Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$4.13 USD

4.13
1,384,226

-0.16 (-3.73%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $4.12 -0.01 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (102 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -80% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls

by Zacks Equity Research

Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.

Zacks Equity Research

Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down

by Zacks Equity Research

IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.

Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -77.78% and 2.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Implied Volatility Surging for Ironwood (IRWD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Ironwood (IRWD) stock based on the movements in the options market lately.

Zacks Equity Research

Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.

Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 9.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50% and 1.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for July 23rd

by Zacks Equity Research

ALK, DINO and IRWD have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2024.